Blood test may predict COVID-19 severity, study finds
NCT ID NCT07466524
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether a blood test measuring suPAR levels can predict which adults hospitalized with COVID-19 will develop severe breathing failure requiring a breathing tube. Researchers analyzed stored blood samples from about 367 patients. The goal was to see if a suPAR level of 6 ng/mL or higher could identify high-risk patients early, potentially helping doctors make better treatment decisions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Michigan state university, Department of Biostatistics
Ann Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?